ADI-PEG20 Clinical Trials (2026): 4 Studies for Hepatocellular Carcinoma & Advanced Hepatocellular Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 ADI-PEG20 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Hepatocellular Carcinoma & Advanced Hepatocellular Carcinoma) and 480 total planned enrollment. 1 Phase 3 ADI-PEG20 trial and 3 Phase 2 are listed. 3 ADI-PEG20 clinical trials are actively recruiting. Most recent activity: NCT05317819 (Dec 2028).
ADI-PEG20 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | withdrawn | Total |
|---|---|---|---|
| P2 | 2 | 1 | 3 |
| P3 | 1 | 1 |
Recruiting ADI-PEG20 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | P3 | Hepatocellular Carcinoma | 300 | Mar 2022 |
| NCT05842512 | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH | P2 | Nonalcoholic Steatohepatitis (NASH) | 60 | Sep 2023 |
| NCT06034977 | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 120 | Dec 2023 |
ADI-PEG20 clinical trials by indication
Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05317819 | — | P3 | recruiting | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma |
| NCT06034977 | — | P2 | recruiting | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma |
Obesity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05829239 | ADI-PEG20 | P2 | withdrawn | ADI-PEG20, Obesity and Prediabetes |
Nonalcoholic Steatohepatitis (NASH) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05842512 | — | P2 | recruiting | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH |
ADI-PEG20 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ADI-PEG20 | NCT05829239 | P2 | withdrawn | Obesity | 0 | — |
Terminated and withdrawn ADI-PEG20 trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05829239withdrawnADI-PEG20, Obesity and Prediabetes
All ADI-PEG20 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | P3 | recruiting | 300 | Polaris Group | Mar 2022 | |
| NCT05842512 | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH | P2 | recruiting | 60 | Polaris Group | Sep 2023 | |
| NCT06034977 | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma | P2 | recruiting | 120 | Chang Gung Memorial Hospital | Dec 2023 | |
| NCT05829239 | ADI-PEG20 | ADI-PEG20, Obesity and Prediabetes | P2 | withdrawn | 0 | Washington University School of Medicine | Apr 2024 |
ADI-PEG20 clinical trials: frequently asked questions
- How many ADI-PEG20 clinical trials are there?
- 4 ADI-PEG20 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are ADI-PEG20 clinical trials recruiting in 2026?
- Yes — 3 ADI-PEG20 trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is ADI-PEG20 being studied for?
- ADI-PEG20 is being studied for Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis (NASH), Obesity, PreDiabetes. The trials are grouped by indication on this page.
- What phase is ADI-PEG20 in?
- ADI-PEG20 clinical trials span 1 Phase 3, 3 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ADI-PEG20 clinical trials?
- The lead sponsor across the most ADI-PEG20 trials is Polaris Group, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ADI-PEG20as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: